You are here

RECOMBINANT DNA-DERIVED PERTUSSIS SUBUNIT VACCINE

Award Information
Agency: Department of Health and Human Services
Branch: N/A
Contract: N/A
Agency Tracking Number: 4684
Amount: $500,000.00
Phase: Phase II
Program: SBIR
Solicitation Topic Code: N/A
Solicitation Number: N/A
Timeline
Solicitation Year: N/A
Award Year: 1988
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
1909 Oak Terrace Lane
Thousand Oaks, CA 91320
United States
DUNS: N/A
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 W Neal Burnette
 Principal Investigator
 (805) 499-5725
Business Contact
Phone: () -
Research Institution
N/A
Abstract

PERTUSSIS IS A DISEASE OF GLOBAL SIGNIFICANCE THAT PARTICULARLY AFFECTS INFANTS DURING THE FIRST YEAR OF LIFE. CURRENTLY LICENSED PERTUSSIS VACCINES ARE HIGHLY EFFICACIOUSBUT QUESTIONS REGARDING THEIR SAFETY HAVE LED TO PUBLIC FEARS OF VACCINE-RELATED INJURIES. THESE INVESTIGATIONS EXAMINE THE POSSIBILITY OF PRODUCING A SUBUNIT VACCINE COMPOSED OF PERTUSSIS ANTIGENS EXPRESSED IN HETEROLOGOUS HOSTS BY VIRTUE OF RECOMBINANT DNA METHODOLOGY. IN PRELIMINARY EXPERIMENTS, SPECIFIC ANTIGENIC COMPONENTS OF THE BACTERIUM BELIEVED CAPABLE OF ELICITING OR AUGMENTING PROTECTIVE IMMUNE RESPONSES AGAINST DISEASE WILL BE ISOLATED. THESE COMPONENTS ARE: (1) THE S-1 SUBUNIT OF THEPERTUSSIS TOXIN; (2) THE 58,000-DALTON SUBUNIT OF THE FILAMENTOUS HEMAGGLUTININ; AND (3) EACH OF THREE SEROTYPE- SPECIFIC FIMBRIAL AGGLUTINOGENS. N-TERMINAL AMINO ACID SEQUENCES WILL BE OBTAINED FOR EACH POLYPEPTIDE WITH A GAS-PHASE MICROSEQUENATOR. A SERIES OF OLIGONUCLEOTIDE PROBES REPRESENTING PREDICTED NUCLEOTIDE SEQUENCES ENCODING EACH ANTIGEN WILL BE SYNTHESIZED AND USED AS HYBRIDIZATION PROBES TO ISOLATE THE GENES FOR THESE PROTEINS FROM B. PERTUSSIS GENOMIC LIBRARIES. IN LATER INVESTIGATIONS, THESEGENES WILL BE INSTALLED IN HOST-VECTOR SYSTEMS CAPABLE OF HIGH-LEVEL EXPRESSION OF HETEROLOGOUS PROTEINS. THE RECOMBINANT-DERIVED PROTEINS SUBSEQUENTLY PRODUCED WILL BE ASSESSED FOR IMMUNOPOTENCY IN EXPERIMENTAL ANIMALS.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government